Gangliosides from human melanoma immunomodulate response of T cells to interleukin-2.

[1]  R. Saxton,et al.  Gangliosides of human melanoma. , 1987, Journal of the National Cancer Institute.

[2]  R. Saxton,et al.  Ganglioside GM2 on the K562 cell line is recognized as a target structure by human natural killer cells , 1987, International journal of cancer.

[3]  E. Korn,et al.  Variations in functional immunocompetence of individual tumor-draining lymph nodes in humans. , 1987, Cancer research.

[4]  A. Cochran,et al.  Suppressor cell activity in melanoma-draining lymph nodes. , 1987, Cancer research.

[5]  R. Robb.  The suppressive effect of gangliosides upon IL 2-dependent proliferation as a function of inhibition of IL 2-receptor association. , 1986, Journal of immunology.

[6]  S. Spiegel,et al.  Direct evidence that endogenous GM1 ganglioside can mediate thymocyte proliferation. , 1985, Science.

[7]  M. Herlyn,et al.  Recombinant gamma-interferon induces changes in expression and shedding of antigens associated with normal human melanocytes, nevus cells, and primary and metastatic melanoma cells. , 1985, Journal of immunology.

[8]  S. Hakomori,et al.  Aberrant glycosylation in cancer cell membranes as focused on glycolipids: overview and perspectives. , 1985, Cancer research.

[9]  R. Saxton,et al.  Immunogenicity of melanoma‐associated gangliosides in cancer patients , 1985, International journal of cancer.

[10]  L. Ulsh,et al.  Modulation of the immune response by gangliosides. Inhibition of adherent monocyte accessory function in vitro. , 1984, The Journal of clinical investigation.

[11]  W. Greene,et al.  Low and high affinity cellular receptors for interleukin 2. Implications for the level of Tac antigen , 1984, The Journal of experimental medicine.

[12]  R. Robb.  Interleukin 2: the molecule and its function. , 1984, Immunology today.

[13]  S. Hakomori,et al.  Ganglioside-mediated modulation of cell growth, growth factor binding, and receptor phosphorylation. , 1984, The Journal of biological chemistry.

[14]  G. Caldini,et al.  Binding of interleukin 2 to gangliosides , 1984, FEBS letters.

[15]  J. Kirkwood,et al.  Gangliosides of normal and neoplastic human melanocytes. , 1984, Biochemical and biophysical research communications.

[16]  S. Hakomori,et al.  Factors affecting expression of glycolipid tumor antigens: influence of ceramide composition and coexisting glycolipid on the antigenicity of gangliotriaosylceramide in murine lymphoma cells. , 1983, Cancer research.

[17]  L. Old,et al.  Human melanoma antigen AH is an autoantigenic ganglioside related to GD2 , 1982, The Journal of experimental medicine.

[18]  D. Galloway,et al.  Human melanoma-associated antigens: role of carbohydrate in shedding and cell surface expression. , 1981, Journal of immunology.

[19]  G. Zwingelstein,et al.  Lipid composition of human malignant melanoma tumors at various levels of malignant growth. , 1979, European journal of biochemistry.

[20]  G. Zwingelstein,et al.  Alteration of gangliosides in plasma and red cells of humans bearing melanoma tumors. , 1978, Biochemical and biophysical research communications.

[21]  R. Gallo,et al.  Selective in vitro growth of T lymphocytes from normal human bone marrows. , 1976, Science.